Labgenomics Co

Labgenomics Co Gross Margin

The Gross Margin of Labgenomics Co (084650.KQ) as of Nov 5, 2026 is 34.76 %. In the previous year, Gross Margin was 36.56 % — a change of -4.94% (lower).

Gross Margin

34.76 %

YoY

-4.94%

Last updated:

Gross Margin of Labgenomics Co is 2025 34.76 % . Gross Margin of Labgenomics Co was 2024 36.56 % . It decreases by -4.94% lower compared to the previous year.

Labgenomics Co's gross margin stands at 34.8%, down from 62.0% several years earlier.

The Labgenomics Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
34.27 KRW
Jan 1, 2019
40.36 KRW
Jan 1, 2020
60.05 KRW
Jan 1, 2021
61.96 KRW
Jan 1, 2022
66.84 KRW
Jan 1, 2023
51.01 KRW
Jan 1, 2024
36.56 KRW
Jan 1, 2025
34.76 KRW
The Labgenomics Co Gross Margin history
YEARGross MarginYoY
34.76 %-4.94%
36.56 %-28.32%
51.01 %-23.69%
66.84 %+7.88%
61.96 %+3.18%
60.05 %+48.80%
40.36 %+17.77%
34.27 %-10.17%
38.15 %-14.66%
44.70 %-6.89%
48.00 %-1.32%
48.64 %+9,615.26%
0.50 %+4.53%
0.48 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labgenomics Co Stock analysis

What does Labgenomics Co do? LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments. Labgenomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labgenomics Co stock

Gross Margin of Labgenomics Co is 34.76 % in 2025.

Gross Margin of Labgenomics Co changed from 36.56 % to 34.76 %, representing a -4.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Labgenomics Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Labgenomics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Labgenomics Co

All Key Metrics — Labgenomics Co